Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 63.27 Billion | USD 107.80 Billion | 6.1% | 2023 |
According to the report published by Zion Market Research, the global Autoinjector Market size was valued at USD 63.27 Billion in 2023 and is predicted to reach USD 107.80 Billion by the end of 2032. The market is expected to grow with a CAGR of 6.1% during the forecast period. The report analyzes the global Autoinjector Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Autoinjector industry.
An autoinjector is an effective mode of administration for intramuscular drugs. Typically, it is a syringe with a pre-charged dosage of drugs with a spring-charged needle. It triggers and delivers a measured drug dose into the body with the sliding motion. These autoinjectors are massively utilized for medical & emergency treatment, epinephrine self-administration, and by migraine sufferers. Autoinjectors offer several advantages like enhancing effectiveness, assuring dosage quality continuity, lowering the needle stuck accident cases, and also lowering the syringe-associated phobia disorder. Autoinjectors are known to maintain the high accuracy of drug dosage when compared to other options.
The global autoinjector market is likely to project subsequent growth with a healthy CAGR of 17.4 2% during the forecast period, largely due to the massive use of anaphylaxis, food allergens, adrenaline, and epinephrine injectors. Autoinjector holds a lot of benefits for both healthcare professionals and patients. These factors have improved compliance & safety and lowered anxiety while also simplifying self-administration. Almost all the present-day diseases have treatment therapies which are administered majorly through injections.
Additionally, injections have always been scary to a huge patient population which is the primary reason for the non-adherence to the treatment. As a result, these autoinjectors have effectively addressed the issues by manufacturing syringes with accurate depth while offering tolerability of administration and comfort when compared to the other manual syringes. The growing innovations in device function and material of autoinjectors will further scale up the growth of the global autoinjector market.
Furthermore, the demand and production of biologics coupled with the constantly aging population globally will also expand the scope of autoinjectors. The ongoing research activities for acute diseases like rheumatoid arthritis, multiple sclerosis, and others are paving the way for the positive trajectory of the global market. The Covid-19 pandemic has significantly impacted the growth of the global market.
Most of the in-hospital therapies and nonessential procedures were halted in the first half of the Covid-19 to contain the spread of the virus. But the overall effect of a pandemic is likely to have a positive impact on the global autoinjector market as the demand for effective remote monitoring and home care devices has scaled up the need for autoinjectors for patients to easily manage chronic illness.
The global market can be segmented into the distribution channel, therapeutic application, design, product type, and region.
By distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and others.
By therapeutic application, the market can be segmented into diabetes, multiple sclerosis, rheumatoid arthritis, anaphylaxis, and others. The rheumatoid arthritis segment accounts for the largest share in the global autoinjector market due to its growing cases globally.
By design, the market can be segmented into standardized and customized.
By product type, the market can be segmented into reusable and disposable.
Disposable autoinjectors account for the largest share in the global autoinjector market due to the growing awareness among people regarding proper hygiene and infection transfer cases. Furthermore, the ease of use and patient friendliness with autoinjectors will also contribute towards the growth of the segment significantly.
Report Attributes | Report Details |
---|---|
Report Name | Autoinjector Market |
Market Size in 2023 | USD 63.27 Billion |
Market Forecast in 2032 | USD 107.80 Billion |
Growth Rate | CAGR of 6.1% |
Number of Pages | 202 |
Key Companies Covered | Gerresheimer, Abbvie, Consort Medical, Owen Mumford, Biogen Idec, Ypsomed AG, Teva Pharmaceutical Industries Ltd, SHL Medical, Novartis AG, Mylan N.V., Johnson and Johnson, Eli Lilly and Company, and Becton Dickinson and Company |
Segments Covered | By distribution channel, By therapeutic application, By design, By product type and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America accounts for the largest share in the global autoinjector market due to the growing awareness among people regarding the benefits offered by autoinjectors. Also, growing cases of rheumatoid arthritis in the region are further likely to strengthen the demand.
Asia Pacific is another leading region in the global market due to the growing disposable income of people in the region.
Some of the significant players in the global autoinjector market include
By distribution channe
By therapeutic application
By design
By product type
FrequentlyAsked Questions
The global autoinjector market is likely to project subsequent growth with a healthy CAGR of 17.4 2% during the forecast period, largely due to the massive use of anaphylaxis, food allergens, adrenaline, and epinephrine injectors. Autoinjector holds a lot of benefits for both healthcare professionals and patients.
Some of the significant players in the global autoinjector market include Gerresheimer, Abbvie, Consort Medical, Owen Mumford, Biogen Idec, Ypsomed AG, Teva Pharmaceutical Industries Ltd, SHL Medical, Novartis AG, Mylan N.V., Johnson and Johnson, Eli Lilly and Company, and Becton Dickinson and Company.
North America accounts for the largest share in the global autoinjector market due to the growing awareness among people regarding the benefits offered by autoinjectors. Also, growing cases of rheumatoid arthritis in the region are further likely to strengthen the demand.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed